2016•Thrombosis ResearchRequires access

Idarucizumab for dabigatran reversal – Does one dose fit all?

Amihai Rottenstreich, Nivin Jahshan, Limor Avraham, Yosef Kalish

Open publisher page 24 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Dabigatran, Idarucizumab, Medicine, Warfarin, Direct thrombin inhibitor, Atrial fibrillation, Antithrombins, Discovery and development of direct thrombin inhibitors